Press Releases UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
14.3 ^USD	+0.28%		+1.06%	-4.67%

Apr. 15	UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	MT
Apr. 03	UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024	May. 04	BU
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial	May. 04	BU
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024	May. 03	BU
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers	Apr. 17	BU
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	Apr. 16	AQ
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer	Apr. 15	BU
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals	Apr. 03	BU
UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102	Mar. 15	AQ
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102	Mar. 14	BU
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 11	AQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 08	BU
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024	Mar. 04	BU
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference	Feb. 26	BU
UroGen Pharma to Participate at Upcoming Investor Conferences	Feb. 01	BU
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102	Jan. 24	BU
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers	Jan. 17	BU
UroGen Pharma to Participate in the B. Riley Healthcare Conference	Jan. 11	BU
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Dec. 11	AQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 08	BU
UroGen Pharma Reports Third Quarter 2023 Financial Results	Nov. 14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Press Releases

Filters